PMID- 16343276
OWN - NLM
STAT- MEDLINE
DCOM- 20060301
LR  - 20151119
IS  - 0902-4441 (Print)
IS  - 0902-4441 (Linking)
VI  - 76
IP  - 1
DP  - 2006 Jan
TI  - Development of rapidly progressive liver light chain deposition under VAD 
      chemotherapy in multiple myeloma.
PG  - 83-5
AB  - Light chain deposition disease (LCDD) is a multisystemic disorder seen in the 
      setting of plasma cell dyscrasias. The histological characteristic of this 
      disorder is the deposition of a homogeneous, granular, slightly eosinophilic and 
      non-Congophilic material that shows immunostaining for monoclonal light chains 
      (kappa or gamma), while in primary amyloidosis (AL) the proteinaceous substance 
      is fibrillar and Congo red positive. In contrast with AL, the light chain in LCDD 
      is usually of the kappa-type. Renal involvement, resulting in nephrotic syndrome, 
      is usually the prominent feature of LCDD. Patients with this disease may also 
      have heart, liver or other organ involvement, mimicking the picture of primary 
      systemic amyloidosis. However, liver failure has rarely been described in 
      patients with LCDD. A patient with myeloma-associated LCDD who developed rapidly 
      progressive liver kappa light chain deposition with fatal outcome after 
      undergoing the first cycle of vincristine/doxorubicin/dexamethasone chemotherapy 
      is reported.
FAU - Samanez, Cesar
AU  - Samanez C
AD  - Department of Oncology, Instituto de Enfermedades Neoplasicas, Surquillo, Peru.
FAU - Domingo, Abel
AU  - Domingo A
FAU - Cibeira, M Teresa
AU  - Cibeira MT
FAU - Miquel, Rosa
AU  - Miquel R
FAU - Soler, Manel
AU  - Soler M
FAU - Blade, Joan
AU  - Blade J
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - England
TA  - Eur J Haematol
JT  - European journal of haematology
JID - 8703985
RN  - 0 (Amyloid)
RN  - 0 (Anti-Inflammatory Agents)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Immunoglobulin kappa-Chains)
RN  - 5J49Q6B70F (Vincristine)
RN  - 7S5I7G3JQL (Dexamethasone)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Amyloid/*metabolism
MH  - Amyloidosis/complications/drug therapy/metabolism/*pathology
MH  - Anti-Inflammatory Agents/administration & dosage
MH  - Antineoplastic Agents/administration & dosage
MH  - Dexamethasone/administration & dosage
MH  - Doxorubicin/administration & dosage
MH  - Fatal Outcome
MH  - Humans
MH  - Immunoglobulin kappa-Chains/*metabolism
MH  - Liver/metabolism/*pathology
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/complications/drug therapy/metabolism/*pathology
MH  - Myocardium/metabolism/pathology
MH  - Renal Insufficiency/complications/drug therapy/metabolism/*pathology
MH  - Syndrome
MH  - Vincristine/administration & dosage
EDAT- 2005/12/14 09:00
MHDA- 2006/03/02 09:00
CRDT- 2005/12/14 09:00
PHST- 2005/12/14 09:00 [pubmed]
PHST- 2006/03/02 09:00 [medline]
PHST- 2005/12/14 09:00 [entrez]
AID - EJH561 [pii]
AID - 10.1111/j.1600-0609.2005.00561.x [doi]
PST - ppublish
SO  - Eur J Haematol. 2006 Jan;76(1):83-5. doi: 10.1111/j.1600-0609.2005.00561.x.